News Releases

Month Year

Email Alerts

Aug 11, 2011

Insmed to Present at 2011 Wedbush Securities Life Sciences Management Access Conference
Aug 8, 2011

Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2011
Aug 1, 2011

Insmed Incorporated Announces Clinical Hold on ARIKACE® Phase 3 Clinical Trials
Jul 26, 2011

Insmed to Host 2011 Second Quarter Earnings Conference Call
Jul 18, 2011

Andrea Drucker Joins Insmed as General Counsel
Jun 28, 2011

Insmed Announces its Addition to the Russell 3000® Index
Jun 10, 2011

Insmed's ARIKACE® Demonstrates Sustained Benefit Through Six Cycles of Treatment for Cystic Fibrosis Patients With Pseudomonas Lung Infections
May 10, 2011

Insmed Announces First Quarter 2011 Financial Results

Insmed Announces First Quarter 2011 Financial Results
Apr 26, 2011

Insmed to Host 2011 First Quarter Earnings Conference Call

Insmed to Host 2011 First Quarter Earnings Conference Call
Mar 21, 2011

Insmed Regains NASDAQ Compliance
Mar 21, 2011

Insmed Announces FDA Clearance of IND for Pivotal Phase 3 Trial of ARIKACE™ in Nontuberculous Mycobacteria Indication
Mar 10, 2011

Insmed Announces Fourth Quarter and Full-Year 2010 Financial Results
Mar 3, 2011

Insmed Announces European Medicines Agency Acceptance of Its Pediatric Investigation Plan for ARIKACE™ in the Cystic Fibrosis Pseudomonas Indication
Mar 2, 2011

One-for-10 Reverse Stock Split of Insmed Common Stock Becomes Effective
Mar 1, 2011

Insmed Shareholders Approve Conversion of Series B Conditional Convertible Preferred Stock and Reverse Stock Split
Feb 24, 2011

Insmed to Participate on Phase III and Beyond Panel at 2011 RBC Capital Markets Healthcare Conference
Feb 23, 2011

Insmed to Host Fourth Quarter and 2010 Year-End Earnings Conference Call
Dec 16, 2010

NASDAQ Grants Insmed Incorporated 180-Day Extension to Regain Compliance with Minimum Bid Price Rule
Dec 2, 2010

Insmed Incorporated and Transave, Inc. Announce Business Combination
Nov 3, 2010

Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2010
Oct 26, 2010

Insmed to Host Third Quarter 2010 Conference Call
Aug 4, 2010

Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2010
Jul 28, 2010

Insmed to Host Second Quarter 2010 Conference Call
Jun 21, 2010

Insmed Receives NASDAQ Deficiency Notice Relating to Minimum Bid Price
May 6, 2010

Insmed Announces First Quarter 2010 Financial Results
Apr 22, 2010

Insmed to Host First Quarter 2010 Conference Call
Mar 22, 2010

Pharmaceutical Industry Veteran Nicholas LaBella Jr., MS, RPh, Joins Insmed as Chief Scientific Officer
Mar 15, 2010

Insmed Announces Fourth Quarter and Full-Year 2009 Financial Results
Mar 4, 2010

Insmed Regains NASDAQ Compliance
Mar 3, 2010

Insmed to Host Fourth Quarter and Full-Year 2009 Conference Call
Nov 6, 2009

Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2009
Oct 22, 2009

Insmed To Host Third Quarter 2009 Conference Call
Sep 16, 2009

Insmed Receives NASDAQ Deficiency Notice Relating to Minimum Bid Price
Aug 13, 2009

Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2009
Jul 31, 2009

Insmed to Host Second Quarter 2009 Conference Call
Jul 27, 2009

Insmed Provides Update on Supply of IPLEX(TM)
Jun 30, 2009

Insmed Announces Addition to the Russell 3000(R) Index
Jun 25, 2009

Insmed Announces Results of IPLEX(TM) Phase II Trial in Myotonic Muscular Dystrophy
Jun 15, 2009

Insmed CEO Resigns Due to Health Concerns
May 13, 2009

Insmed Announces First Quarter 2009 Financial Results
May 5, 2009

Insmed Regains NASDAQ Compliance
Apr 23, 2009

Insmed to Host First Quarter 2009 Conference Call
Apr 22, 2009

Insmed to Host First Quarter 2009 Conference Call
Mar 31, 2009

Insmed Completes Sale of Follow-On Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million
Mar 30, 2009

Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM)
Mar 25, 2009

Insmed Announces That NASDAQ Further Extends Temporary Suspension of Minimum Bid Closing Price Rule
Mar 11, 2009

Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results
Mar 10, 2009

Insmed Announces FDA Issues Statement Regarding Position on Allowing Patients With ALS Access to IPLEX(TM) Under an IND
Feb 26, 2009

Insmed to Host Fourth Quarter and Full-Year 2008 Conference Call
Feb 12, 2009

Insmed Sells Follow-on Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million

Show per page

Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your
email alerts.

View the latest Insmed Investor Presentation

Download

Our Global Company

Current Clinical Trials

Our Research Team

Our Global Company

Current Clinical Trials

Our Research Team

Footer